<DOC>
	<DOCNO>NCT02658734</DOCNO>
	<brief_summary>This Phase IV , single-arm , multicenter , open-label clinical trial design assess safety trastuzumab emtansine Indian patient HER2-positive unresectable locally advanced breast cancer ( LABC ) metastatic breast cancer ( mBC ) receive prior treatment trastuzumab taxane .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine Indian Patients With Human Epidermal Growth Factor Receptor 2 ( HER2 ) -Positive Unresectable Locally Advanced Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab Taxane</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Prospectively confirm HER2positive ( i.e. , IHC 3+ IHC 2+ gene amplify fluorescence situ hybridization [ FISH ] positive ) assess primary tumor and/or metastatic site Documented progression unresectable , locally advanced , mBC , determine investigator Left ventricular ejection fraction ( LVEF ) &gt; /= 50 % echocardiogram ( ECHO ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 A negative serum BetaHuman Chorionic Gonadotropin ( BetaHCG ) test woman childbearing potential ( premenopausal meeting definition postmenopausal i.e . &gt; /= 12 month amenorrhea ) , woman undergo surgical sterilization ( i.e. , absence ovary and/or uterus ) For woman childbearing potential : agreement remain abstinent ( refrain heterosexual intercourse ) use two adequate nonhormonal method contraception , include least one method failure rate &lt; 1 % per year , treatment period least 7 month last dose study drug For men : agreement remain abstinent ( refrain heterosexual intercourse ) use contraceptive measure agreement refrain donate sperm . With female partner childbearing potential , men must remain abstinent use condom plus additional contraceptive method together result failure rate &lt; 1 % per year treatment period least 7 month plus 90 day ( spermatogenesis cycle ) last dose study drug . Men must refrain donating sperm period . With pregnant female partner , men must remain abstinent use condom treatment period least 7 month last dose study drug . Prior treatment trastuzumab emtansine Prior treatment lapatinib lapatinib capecitabine noncomparable biologic biosimilar trastuzumab Peripheral neuropathy Grade &gt; /= 3 per National Cancer Institute 's Common Terminology Criteria Adverse Events ( NCI CTCAE [ version 4.03 ] ) History malignancy within previous 5 year , except appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage 1 uterine cancer , synchronous previously diagnose HER2positive breast cancer , cancer similar curative outcome mention History receive anticancer drug/biologic investigational treatment within 21 day prior enrollment except hormone therapy , give 7 day prior enrollment ; recovery treatmentrelated toxicity consistent eligibility criterion History exposure cumulative dos anthracyclines , define protocol History radiation therapy within 14 day enrollment Brain metastasis untreated , symptomatic , require therapy control symptom , well history radiation , surgery , therapy , include steroid , control symptom brain metastasis within 2 month ( 60 day ) enrollment History decrease LVEF &lt; 40 % symptomatic congestive heart failure ( CHF ) previous trastuzumab treatment History symptomatic chronic heart failure ( New York Heart Association [ NYHA ] Classes IIIV ) serious cardiac arrhythmia require treatment History myocardial infarction unstable angina within 6 month enrollment Current dyspnea rest due complication advance malignancy requirement continuous oxygen therapy Current severe , uncontrolled systemic disease Pregnancy lactation Concurrent , serious , uncontrolled infection current know infection human immunodeficiency virus ( HIV ) active hepatitis B and/or hepatitis C. For patient know carrier hepatitis B virus ( HBV ) , active hepatitis B infection must rule , base negative serologic test and/or determination HBV DNA viral load per local guideline Presence condition could affect gastrointestinal absorption : malabsorption syndrome , resection small bowel stomach , ulcerative colitis History intolerance ( Grade 34 infusion reaction ) know hypersensitivity trastuzumab murine proteins component product Assessed investigator unable unwilling comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>